Glenmark Pharmaceuticals Inc has received United States Food & Drug Administration (FDA) approval for Dapagliflozin tablets, 5 mg and 10 mg, the generic version of Farxiga tablets, 5 mg and 10 mg, of AstraZeneca AB.
According to IQVIATM sales data for the 12 month period ending January 2020, the Farxiga tablets, 5mg and 10 mg market achieved annual sales of approximately $1.8 billion.
Also read: India to spend $1.3 billion to boost pharma production
Glenmark’s current portfolio consists of 165 products authorized for distribution in the US market and 45 ANDA’s pending approval with the US FDA.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
